IDWeek 2024: Moderna’s norovirus vaccine mRNA-1403 shows …
Oct 21, 2024 · At IDWeek 2024, Moderna presented interim results from an ongoing Phase I/II, randomised, observer-blind, placebo-controlled, dose-ranging trial (NCT05992935) for mRNA …
MHRA expects new UK clinical trial regulation implementation by …
Oct 16, 2024 · Between 2022 and 2023, the MHRA undertook a consultation period surrounding a new legislative framework for clinical trials in the UK. The MHRA said the new regulation will …
GSK ceases HSV vaccine - a chance for Moderna and BioNTech
Sep 25, 2024 · GSK recently announced the discontinuation of its herpes simplex virus (HSV) therapeutic vaccine candidate, GSK3943104, following the failure of a Phase I/II clinical trial to …
Arrowhead seeks approval to commence RNAi therapy trial
Dec 4, 2024 · Arrowhead Pharmaceuticals has submitted an application to the New Zealand Medicines and Medical Devices Safety Authority seeking clearance to commence a Phase I/IIa …
Cidara achieves full enrolment in influenza prevention trial
Dec 5, 2024 · Cidara Therapeutics has achieved full planned subject enrolment for the randomised Phase IIb NAVIGATE trial designed to assess the safety and efficacy of its drug …
A schizophrenia win for BMS’ Cobenfy, but challenges lie ahead
Oct 1, 2024 · Cobenfy is also being developed as an adjunctive therapy in patients who have an inadequate response to atypical antipsychotic monotherapy. The ongoing Phase III ARISE trial …
Lebrikizumab, Tralokinumab and Dupilumab compete in AD space
Oct 8, 2024 · Lebrikizumab, tralokinumab and dupilumab to compete in atopic dermatitis space. The separation of Ebglyss from Dupixent and Adbry/Adtralza will depend on real-world clinical …
SELLAS announces data of key predictor of response to SLS009
Nov 28, 2024 · SELLAS Life Sciences Group has announced positive data from preclinical studies identifying the ASXL1 mutation as a significant predictor of response to SLS009, a selective …
BioArctic doses first subject in Parkinson’s disease therapy trial
Dec 6, 2024 · BioArctic has dosed the first subject with the monoclonal antibody, exidavnemab, in the randomised Phase IIa EXIdavnemab Synucleinopathy Trial (EXIST) to treat Parkinson’s …
AHA 2024: Zerlasiran shows promising Phase II results for elevated ...
Nov 19, 2024 · Dr. Steven Nissen, MD chairman and chief academic officer of the Heart and Vascular Institute at the Cleveland Clinic and professor of medicine at the Lerner College of …